-
Shanxi deploys public health system construction: public hospitals are upgraded from quantity to quality
Time of Update: 2022-01-08
Promote the high-quality development of medical institutions, improve the disease prevention and control system, and promote the inheritance and development of traditional Chinese medicine. . . On D
-
More than 10,000 drugs have been suspended from the Internet!
Time of Update: 2022-01-07
com, the size of the terminal chemical drug market in physical pharmacies in key cities in 2020 will exceed 50 billion yuan, of which atorvastatin calcium tablets top the list with 1.
-
Strengthen the quality and safety supervision of traditional Chinese medicine and promote the high-quality development of traditional Chinese medicine
Time of Update: 2022-01-07
The drug regulatory authority strictly implements territorial regulatory responsibilities, severely investigates and handles cases of violations of laws and regulations in the production of traditional Chinese medicine, urges enterprises to effectively implement the main responsibility, promotes the successful completion of various objectives and tasks of quality and safety supervision of traditional Chinese medicine, and promotes the continuous improvement of the overall quality of traditional Chinese medicine .
-
The Chinese medicine market continues to expand, leading Chinese medicine companies are worthy of attention
Time of Update: 2022-01-07
a series of heavy documents were released, which continued to promote the innovation and high-quality development of the Chinese medicine industry, as well as the continuous expansion of the market .
7 billion yuan, with an average annual compound growth rate.
-
good news!
Time of Update: 2022-01-07
Compared with the original market price, through negotiation of price reduction and medical insurance reimbursement, this negotiation is expected to reduce the burden of patients by more than 30 billion yuan in 2022 .
-
In 2022, the industry recommends paying attention to these pharmaceutical investment opportunities!
Time of Update: 2022-01-07
Specifically, investment opportunities in at least five sub-sectors, including innovative drugs, innovative medical devices, medical services, medical consumption, and CXO, are worthy of attention .
-
The announcement period of the 2021 annual report is approaching, and the performance of these pharmaceutical companies is expected to increase!
Time of Update: 2022-01-07
Kaipu Biological expects that the net profit attributable to shareholders of listed companies in 2021 will be 800 million to 860 million yuan, a year-on-year increase of 120.
-
In 2022, pharmaceutical products that are popular in the industry will show three major characteristics
Time of Update: 2022-01-07
In addition to the annual performance forecasts of many pharmaceutical machinery companies, a large number of companies have launched A series of new products and solutions that are quite eye-catching continue to help the entire industry continue to accelerate its development in the direction of high quality .
-
The domestic innovative drug industry is ushering in a period of opportunity!
Time of Update: 2022-01-07
In addition, it should be noted that with the increasing prosperity of innovative drugs, the R&D and commercial production needs of pharmaceutical companies have begun to continue to expand, which is placing higher requirements on the speed and flexibility of production line construction.
-
CS5001 clinical trial application by CStone Pharmaceuticals was approved by the U.S. FDA
Time of Update: 2022-01-07
According to the press release, this is a potential "best-in-class" antibody-conjugated drug (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1).
CS5001 is an ADC targeting ROR1 with many differentiated features, including proprietary site-specific coupling, tumor-selective cleavable linker and prodrug technology .
-
Over 2.5 billion large varieties of Xinlitai have been reviewed
Time of Update: 2022-01-07
On December 28, the official website of the State Food and Drug Administration showed that Xinlitai's cefoxitin sodium for injection passed the consistency evaluation and was the third in China .
-
Overview of DS patent expiring drugs in the Orange Book of the United States in 2021 (excerpt)
Time of Update: 2022-01-07
In order to promote the development of China’s generic drug industry and give back to the partners of the China Pharmaceutical Industry Information Center (hereinafter referred to as the Information Center), the information center uses its own powerful data platform to collect and sort out some information on core patent expired drugs in 2021 for domestic imitation.
-
Heavy!
Time of Update: 2022-01-07
The guiding ideology for development, puts forward five "persistence" overall principles and main development goals, and formulates 10 major tasks to ensure drug safety during the "14th Five-Year Plan" period, promote high-quality drug development, and promote drug regulatory systems and supervision Modernize capabilities to protect and promote public health .
-
At the end of the year, a large number of senior executives of pharmaceutical companies were still "running away"
Time of Update: 2022-01-07
Aoyuan Meigu: A number of executives "leave" Aoyuan Meigu announced on the evening of December 29 that the company's board of directors received the resignation report from Chairman Ma Jun, Director Chen Yong, Independent Director Zhang Shujun, President Hu Ran, and Executive President Fan Shijie .
-
With a new year and a new look, a batch of new drugs has made progress!
Time of Update: 2022-01-07
Genting Shinyao: Gosatuzumab new drug listing application accepted in Taiwan, China Recently, Genting Shinyao, a biopharmaceutical company focused on the development and commercialization of innovative drugs, announced that the Food and Drug Administration of Taiwan, China has accepted the gosatuzumab list The new anti-drug application is for the treatment of locally advanced or metastatic triple-negative breast cancer that is unresectable in adult patients.
-
Year-end inventory of hot events in the pharmaceutical industry in 2021
Time of Update: 2022-01-07
Including the monopoly of raw materials medicines issued a 100 million yuan fine; the sixth batch of special collections landed, and the price of insulin was greatly reduced; the results of the new round of medical insurance negotiations were released, and the rare disease drugs that used to be "700,000 per shot" will be about 30,000 yuan.
-
The medical insurance "green channel" of Chinese medicine has been opened up!
Time of Update: 2022-01-07
Among them, general TCM medical service items can continue to be paid on a per-item basis, TCM institutions may not implement DRG payment for the time being, and TCM decoction pieces will continue to be added to the 25% policy, which makes a large group of western medicine manufacturers who are suffering from a cost control crisis enviable .
-
The pharmaceutical equipment industry is facing a new change!
Time of Update: 2022-01-07
It is worth mentioning that Chutian Technology also proposed that a new change it is now facing is the increase in industry concentration, whether it is the pharmaceutical industry or the pharmaceutical equipment industry .
-
More than 400 pharmaceutical companies have more than 167,000 R&D personnel, and the R&D speed continues to increase
Time of Update: 2022-01-07
In addition, data shows that Hengrui Pharmaceuticals has also continuously increased its R&D investment in recent years.
In recent years, Shanghai Pharmaceuticals has continuously increased its investment in research and development, and its R&D team has also been continuously expanded .
-
Where will the pharmaceutical industry head in 2022?
Time of Update: 2022-01-07
Looking back at 2021, after a whole year of valuation digestion in the pharmaceutical sector, internal differentiation continued, and innovations continued to explore breakthroughs, and the industry gradually matured .
